Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;335:1057-1058 (24 November), doi:10.1136/bmj.39365.511076.BE
Guidelines on the use of digoxin are inconsistent with evidence from randomised trials
| The first 150 words of the full text of this article appear below. |
Atrial fibrillation is the most common cardiac arrhythmia and it causes substantial morbidity, especially in elderly people. In June 2006, the UK National Institute for Health and Clinical Excellence (NICE) published new guidelines for control of heart rate in people with chronic atrial fibrillation.1 The guidelines depart from historical practice by recommending that instead of digoxin, β adrenoceptor blockers or rate limiting calcium antagonists should be the preferred initial monotherapy, except in predominantly sedentary people. Similarly, the revised 2006 joint American College of Cardiology/American Heart Association/European Society of Cardiology (ACC/AHA/ESC) guidelines recommend the use of β blockers or calcium antagonists alone to control heart rate.2 We have reviewed the evidence to support this fundamental change in practice and challenge its safety.
No single definition of ideal control of heart rate in chronic atrial fibrillation exists.3 Rate control drugs aim to reduce heart rate at rest and during exercise, without causing
Theodora Nikolaidou, research fellow, Kevin S Channer, consultant cardiologist and physician
Royal Hallamshire Hospital, Sheffield S10 2JF
nikolaidou@btinternet.com
Read all Rapid Responses